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Introduction  
Children with chronic granulomatous disease (CGD) and cystic fibrosis (CF) share 
some important clinical characteristics which are the consequence of their intrinsic 
susceptibility to recurrent and opportunistic infections and exaggerated inflammation. 
Although the clinical phenotypes of Aspergillus disease differ substantially between 
those two non-neutropenic patient groups, the underlying pathophysiology show 
remarkable commonalities with excessive inflammation being a hallmark of 
Aspergillus disease. The occurrence of Aspergillus infections in these two patient 
populations is associated with decreased quality of life and premature death. 
Our knowledge of the pathophysiology of Aspergillus infections is mainly derived 
from infections caused by a single species - Aspergillus fumigatus - in the 
neutropenic host. The insights obtained in this setting do not translate well to the 
non-neutropenic host. Recently, more insight has been obtained in the underlying 
molecular mechanisms driving the excessive inflammation during Aspergillus 
infection and disease in those 2 patient groups and is summarized here.  
 
Chronic granulomatous disease 
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency 
(prevalence 1:200,000) characterized by a defective NADPH-oxidase in phagocytic 
cells. Patients with CGD have the highest lifetime risk of invasive aspergillosis (IA; 
incidences 26%-45%) and, despite the availability of antifungal prophylaxis and 
targeted antifungal therapy, IA remains the most common infectious complication 
and the most frequent cause of death in CGD [1]. Aspergillus-specific mortality in 
CGD appears to be decreasing over time, from around 30% to below 20% in the 
most recent case series. Curative options to treat CGD, e.g. haematopoietic stem 
cell transplantation, are available, though not each patient is benefiting from this 
treatment. Impaired production of reactive oxygen species (ROS) underlies the 
clinical phenotype of CGD. Lack of the direct microbicidal effects of ROS renders 
children with CGD susceptible to IA, while the lack of a functional NADPH oxidase 
leads to dysregulated inflammatory responses explaining the pathophysiology of IA 
as observed in CGD. Invasive aspergillosis in CGD is characterised by a sub-acute 
infection, non-angio-invasive, excessive granuloma formation in the affected tissue.  
There is a clear association between the NADPH-oxidase mutation, the extent to 
which superoxide production is impaired, and the occurrence and severity of IA in 
CGD.  X-linked CGD patients have both a higher incidence and worse outcome of IA 
compared to those with autosomal recessive CGD. Invasive aspergillosis in CGD is 
caused predominantly by two different Aspergillus species, A. fumigatus and A. 
nidulans. Interestingly, A. nidulans infection is found almost exclusively in patients 
with X-linked CGD, and seldom other (non-CGD) patient groups, indicating a unique 
unsolved interaction in the clinical setting [1]. Both in vitro and murine studies have 
shown that infection with A. nidulans and A. fumigatus induce a hyperinflammatory 
response driven by an exaggerated interleukin-1 (IL-1) production [2,3].  
 
Cystic fibrosis 
Cystic fibrosis (CF) is caused by a mutation in the gene that encodes the cystic 
fibrosis transmembrane conductance regulator (CFTR) protein, an ion channel, 
expressed in epithelial cells as well as immune cells. This mutation accounts for the 
most common fatal genetically inherited disease in humans (prevalence 1:13,500). 
Median age of death is still a mere 29 years and progressive lung damage caused 
by inflammation and infection is the major cause of this fatal outcome. Up to 60% of 
patients with CF will be infected with Aspergillus and it has been suggested that 
persistent infection is associated with progressive lung function decline [4]. A small 
proportion of those patients will develop allergic responses to Aspergillus (e.g. 
allergic bronchopulmonary aspergillosis [ABPA] or fungal sensitization), while others 
will develop airway-invasive aspergillosis (e.g. Aspergillus bronchitis). Studies 
reporting on the relative number of A. fumigatus versus non-fumigatus Aspergillus 
species have shown that between 36% and 58% of colonisation is caused by A. 
fumigatus [5]. Although infection with Aspergillus has long been considered as 
innocent colonisation due to the entrapment of Aspergillus conidia by the sticky 
mucus in the CF lung, recent data suggest otherwise. Adhesion, phagocytosis and 
killing of Aspergillus conidia has been shown to be impaired in CF bronchial 
epithelial cells [6]. In the same paper, the authors demonstrated, by using an 
experimental murine model, impaired clearance of Aspergillus conidia and epithelial 
necrosis and fibrin deposition in CFTR-deficient but not wild-type mouse airways. 
CFTR protein has been found in cells of both the innate and adaptive immune 
system and has shown to play a critical role for their normal function. The 
observation that CF patients have a higher risk of developing invasive aspergillosis 
after lung transplantation than non-CF transplant patients additionally suggests 
impaired antifungal effector mechanisms of CF immune cells [4]. We have recently 
shown that although human CF neutrophils are capable of efficiently phagocytose 
and kill A. fumigatus, this is at a cost of excessive ROS [7]. This excessive ROS 
response was significantly correlated to disease severity in terms of clinical 
exacerbations and lung function and suggests that the hyperinflammatory response 
by CF neutrophils upon exposure to A. fumigatus is likely to contribute to progressive 
lung disease [7]. 
 Immunopathology 
Aspergillus infection triggers an aberrant host immune response characterised by 
hyperinflammation in patients with CGD and CF, resulting in insufficient fungal 
control and tissue damage. Over the last few years a number of studies have shown 
commonalities in the molecular drivers of the observed immunopathology in both 
patients groups. 
Autophagy is the process of effective microbial killing and clearance following 
phagocytosis and phagolysosome maturation, and controls inflammasome 
activation.  Defective autophagy has been reported in both CGD and CF immune 
cells [8,9]. The link between autophagy and ROS remains poorly understood, 
although it is known that reactive oxygen species are essential for effective 
autophagy. On the other hand, excessive ROS production inhibits the process of 
autophagy. Therefore, the observations that the process of autophagy is defective in 
both the CF (excessive reactive oxygen species) as well as the CGD (deficient in 
reactive oxygen species) host suggest a common element to the immunopathology.  
Rapamycin, a macrolide compound, was initially developed as an antifungal agent 
until its potent immunosuppressive properties were discovered. Rapamycin is a 
mTOR (mammalian target of rapamycin) inhibitor and is mainly been used in clinical 
care to prevent rejections of organ transplants and uncontrolled lymphoproliferation. 
A first study showing its potential use in patients with CGD demonstrated that 
rapamycin induced autophagy induction thereby inhibiting inflammasome activation 
in human CGD phagocytes [10]. Inhibition of pro-inflammatory cytokines including 
TNF-α and IL-17, independently of caspase-1 inhibition, was observed as well. 
Anakinra, an IL-1-receptor antagonist, enhanced the inhibitory effect of rapamycin on 
IL-1β secretion by phagocytes in the in vitro model used, suggesting that this 
combination could have extended benefits for dampening the immunopathology in 
CGD. Comparable studies are not performed yet using human CF phagocytes. 
 
Another component in the vicious perpetual cycle of fungal induced inflammation is 
the activation of the inflammasome. Increased activation of the inflammasome has 
been shown under conditions in which either too much or too little reactive oxygen 
species is induced. This pathway has been shown to be upregulated in both CGD 
and CF immune cells upon fungal stimulation and leads to increased release of IL-1 
[3,11]. IL-1 inhibitors like IL-1-receptor antagonists, have shown to reduce 
inflammation in human immune cells and experimental murine models of CGD and 
CF [3,11]. We have shown previously that chloroquine, an antimalarial drug 
exhibiting anti-inflammatory properties, inhibits IL-1 release by Aspergillus infected 
human CGD phagocytes [12]. The mechanisms of the anti-inflammatory activity of 
chloroquine though, is poorly understood. Our recent observations show that 
prophylactic hydroxychloroquine can attenuate mortality, weight loss and pulmonary 
inflammation in gp91-/- mice infected with A. nidulans. This beneficial effect is not 
observed in A. fumigatus infections. Chloroquine and hydroxychloroquine have 
similar pharmacological properties, but hydroxychloroquine has a more favourable 
side effect profile, increasing its appeal for long-term clinical use. 
 
Studies in murine models of pulmonary aspergillosis showed that a defective 
NADPH-oxidase complex and CFTR dysfunction leads to defective indoleamine 2,3-
dioxygenase (IDO) activity [13,14]. Indoleamine 2,3-dioxygenase (IDO) is a rate-
limiting enzyme for tryptophan degradation in the kynurenine pathway. Impaired 
tryptophan catabolism resulted in exaggerated inflammation and abnormalities in T 
cell polarisation with exaggerated Th17 responses. Therapeutic modulation of this 
pathway to enhance IDO activity enabled resolution of excessive inflammation in 
those experimental models. However, subsequent studies have found preserved 
tryptophan/kynurenine metabolism and Th17 differentiation in CGD patients [15], 
suggesting this effect is likely limited to the p47-/- murine model. Studies assessing 
its relevance in patients with CF are lacking.  
 
Immunotherapy 
Corticosteroids are used to dampen the allergic inflammation in ABPA in CF patients 
and the inflammatory complications post-infection in CGD patients [1,2]. Due to the 
well-known severe side-effects and its unspecific and broad mode of action, new and 
more targeted immunotherapies are needed. Interferon-γ has been carefully studied 
as an antifungal adjuvant immunotherapy. Interferon-γ enhances antifungal activity 
of macrophages and polymorphonuclear neutrophils, and its first successful clinical 
application was in CGD patients in whom substantial protection was seen against IA 
[1]. Currently, only sparse preclinical data is available to support the potential 
beneficial effect of novel additional immunomodulatory agents in the management of 
Aspergillus infection in children with CGD or CF.   
The CFTR modulators are the first causative treatment options for CF patients and 
have achieved significant improvement in lung function and quality of life. The results 
of a recent clinical study looking at the effect of Ivacaftor on specific airway microbial 
colonisation showed a 53% reduction in Aspergillus colonisation [16]. This effect may 
be related to a reduction in inflammation, an improved immune function of the 
epithelial cells or a direct effect on immune cells present in the lung environment, or 
a combination of both. 
 
Summary 
Patients suffering from CGD or CF are two non-neutropenic patient populations 
characterized by an increased susceptibility to Aspergillus infections. To improve the 
outcome of Aspergillus infections in these particular patient groups, a better 
understanding of the host-fungus interaction is urgently required in order to develop 
targeted and individualized management strategies. Targeting either the primary 
immune defect, or the defective autophagy, or dampening the activity of the 
inflammasome has the potential to reduce the immunopathology caused by 
Aspergillus species and consequently to improve patient outcome. Yet, the 
translation of the exciting preclinical data into careful designed clinical trials is 
awaited. 
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